Best adjuvant (assist) for chemotherapy | 1+1>487% |
Effectively improve chemotherapy effect, treatment, immunity.
Reduce side effects and recurrence.
Overview / Relation / Abstract / Role / Principle / Action / Mechanism / Function / Work |
Lymphoma - Hodgkin: Latest Research
Abstract / Summary / Overview of Apoptosis.
Why do cells undergo apoptosis?
The relationship between cancer cells and apoptosis.
Where are the weaknesses and symptoms of cancer cells?
Are cancer cells aggressive?
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work)
Solamargine's major function mechanism:
Solamargine vs cancer
Best Chemotherapy Adjuvant. (1+1>478%)
Effectively improve chemotherapy effect and cure.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Extract : https://www.cancer.net/cancer-types/
Lymphoma - Hodgkin: Latest Research
You will read about the scientific research being done to learn more about Hodgkin lymphoma and how to treat it.
Doctors are working to learn more about Hodgkin lymphoma, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the best diagnostic and treatment options for you.
Measuring treatment effectiveness. A focus of research for Hodgkin lymphoma is monitoring how well treatment is working. This knowledge can help inform decisions about whether treatment needs to be changed. Some new clinical trials are looking at changing chemotherapy depending on the results of a PET-CT (positron-emission tomography combined with computed tomography) scan early in the treatment period, usually after 2 cycles. This is called response-adapted treatment. The International Conference on Malignant Lymphomas recommends the use of response-adapted treatment for Hodgkin lymphoma. The results of the PET-CT taken after 2 cycles of first-line treatment are used to generate a Deauville score, which indicates how well the treatment is working. The Deauville score is then used to plan how much and what kind of treatment is needed after the first treatment to give the best results and reduce potential side effects, including late effects. Additional methods for measuring whether treatment is working, such as specialized blood tests (sometimes called liquid biopsies), are being studied.
Reducing treatment intensity. Some types of earlier-stage Hodgkin lymphoma are so often cured that less intense treatment plans are being tested. These lower-intensity plans use chemotherapy alone or lower doses or smaller fields of radiation therapy or lower amounts of chemotherapy. The goal is to effectively treat the lymphoma and have fewer long-term side effects. Often, a PET-CT scan is given after a short course of chemotherapy to help guide these treatment reductions.
New medications and drug combinations. New drugs, new combinations of chemotherapy and immunotherapy, lower doses, and shorter schedules of treatment are being studied in clinical trials to reduce short-term side effects and long-term health risks. Other drugs are being tested for recurrent Hodgkin lymphoma and may be added to the current standard chemotherapy regimens used for progressive disease.
Several new types of drugs that work differently from chemotherapy, called targeted therapy, are also being studied. Recent clinical trials have been studying the benefits and risks of adding brentuximab to the combination of therapies used for first-line treatment of Hodgkin lymphoma. Researchers are also examining the use of nivolumab and pembrolizumab (see “Immunotherapy” in Types of Treatment) in treating both newly diagnosed and recurrent Hodgkin lymphoma. Pembrolizumab plus GVD chemotherapy is being used in clinical trials to treat patients who have recurrent Hodgkin lymphoma and have already received brentuximab vedotin.
Gene profiling. Some researchers are looking at the specific genes and proteins that are found in Hodgkin lymphoma. These genes and proteins provide more information about the behavior of Hodgkin lymphoma, which may help doctors choose which medication to use to treat the lymphoma.
Transplantation approaches. Non-myeloablative or reduced-intensity bone marrow/stem cell transplantation and allogeneic transplantation are being tested for recurrent Hodgkin lymphoma.
Palliative care/supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current Hodgkin lymphoma treatments to improve comfort and quality of life for patients.
Abstract / Summary / Overview of Apoptosis.
Overview of apoptosis
•Programmed cell death
•Apoptosis is a form of programmed cell death, or “cellular suicide.”
•Apoptosis is different from necrosis, in which cells die due to injury.
•Apoptosis removes cells during development, eliminates potentially cancerous and virus-infected cells, and maintains balance in the body.
Why do cells undergo apoptosis?
- Basically, apoptosis is a general and convenient way to remove cells that should no longer be part of the organism.
- Some cells are abnormal and could hurt the rest of the organism if they survive, such as cells with viral infections or DNA damage.
- Apoptosis is part of development
- In many organisms, programmed cell death is a normal part of development.
The relationship between cancer cells and apoptosis
Apoptosis can eliminate infected or cancerous cells.
When a cell’s DNA is damaged, it will typically detect the damage and try to repair it.
If the damage is beyond repair, the cell will normally send itself into apoptosis, ensuring that it will not pass on its damaged DNA.
When cells have DNA damage but fail to undergo apoptosis, they may be on the road to cancer.
However, “successful” cancer cells successfully evade the process of apoptosis.
This allows them to divide out of control and accumulate mutations (changes in their DNA).
Apoptosis is key to immune function
Apoptosis also plays an essential role in the development and maintenance of a healthy immune system.
Where are the weaknesses and symptoms of cancer cells?
The symptoms of cancer cells are in the nucleus.
The nucleus controls the outer cytoplasm, cell composition, cell viability, etc.
DNA mutations also mutate in the nucleus.
Therefore, to treat cancer cells, we must first enter the nucleus.
Let the “regulatory cell gene” mechanism enter the nucleus to regulate
Are cancer cells aggressive?
After the action of Solamargine, the aggressiveness of cancer cells is alleviated.
So after using Solamargine, many patients feel that I am half better.
Although the tumor does not disappear quickly, patients feel that the degree of aggressiveness is reduced.
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work).
Solamargine's major function mechanism:
When Solamargine enter,
Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.
Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.
Reduced drug resistance
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.
Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?
Solamargine vs cancer
Solamargine vs cancer
The picture shows the death of cancer cells.
The black and black parts are cancer cell nuclei.
Even if the nucleus ruptures, the cancer cells will die.
The figure shows that cancer cells can cause death.
The figure shows that cancer cells can cause death.
The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.
The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.
The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.
Best Chemotherapy Adjuvant. (1+1>487%)
Effectively improve chemotherapy effect and treatment.
ANTI-CANCER
Patent protection in 32 nations.
A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.
A comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.
SR-T100 combination therapy with effective result against breast cancer cells.
Combination Therapy | Research results for lung cancer cells.
A. Chemotherapy (100μM), 16% of cancer cell apoptosis.
B. Alone SM (4.8μM), 28% of cancer cell apoptosis.
C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.
D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.
SM has a clearing effect better than Chemotherapy.
The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.
SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).
SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).
Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.
The best solution for cancer cells.